669. HepB-CpG Vaccine in People With HIV and Prior Nonresponse to HBV Vaccine: The BEe-HIVe Trial End-of-Study Results.
作者: Kristen M Marks.;Minhee Kang.;Triin Umbleja.;Andrea Cox.;Karen J Vigil.;Anchalee Avihingsanon.;Patcharaphan Sugandhavesa.;Leolin Katsidzira.;Josphat Kosgei.;Hugo Perazzo.;Jennifer Price.;Stephanie Caruso.;Kevin Knowles.;Beverly L Alston-Smith.;Parita Rathod.;Kenneth E Sherman.; .
来源: JAMA. 2025年334卷10期910-912页 675. Osteoporosis: A Review.
Osteoporosis is characterized by low bone mass, increased bone fragility, and increased susceptibility to fracture, which is associated with substantial morbidity, mortality, and economic costs. Worldwide, 1 in 3 women and 1 in 5 men older than 50 years of age experience osteoporotic fractures in their lifetime.
677. Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension: The Launch-HTN Randomized Clinical Trial.
作者: Manish Saxena.;Luke Laffin.;Claudio Borghi.;Beatriz Fernandez Fernandez.;Jalal K Ghali.;Branko Kopjar.;Krishna Polu.;Simon D Roger.;B T Slingsby.;Frank Strutz.;Liffert Vogt.;Matthew R Weir.;David Rodman.; .
来源: JAMA. 2025年334卷5期409-418页
Uncontrolled hypertension remains a global health concern and dysregulated aldosterone production is a central mechanism. Lorundrostat, a novel aldosterone synthase inhibitor that reduces aldosterone production, demonstrated efficacy in participants with uncontrolled hypertension, including those with treatment-resistant hypertension.
|